XERS - Xeris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
218.66M
Enterprise Value 3
176.74M
Trailing P/E
N/A
Forward P/E 1
-2.62
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
129.23
Price/Book (mrq)
5.00
Enterprise Value/Revenue 3
104.46
Enterprise Value/EBITDA 6
-1.62

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-60.26%
S&P500 52-Week Change 313.25%
52 Week High 321.91
52 Week Low 36.85
50-Day Moving Average 38.48
200-Day Moving Average 310.45

Share Statistics

Avg Vol (3 month) 3164.95k
Avg Vol (10 day) 396.2k
Shares Outstanding 527M
Float 17.18M
% Held by Insiders 16.69%
% Held by Institutions 149.11%
Shares Short (Oct 31, 2019) 42.28M
Short Ratio (Oct 31, 2019) 420.33
Short % of Float (Oct 31, 2019) 49.81%
Short % of Shares Outstanding (Oct 31, 2019) 48.45%
Shares Short (prior month Sep 30, 2019) 42.36M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-6,494.86%

Management Effectiveness

Return on Assets (ttm)-51.70%
Return on Equity (ttm)-162.73%

Income Statement

Revenue (ttm)1.69M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)-44.50%
Gross Profit (ttm)2.42M
EBITDA -109.02M
Net Income Avi to Common (ttm)-112.92M
Diluted EPS (ttm)-4.59
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)102.47M
Total Cash Per Share (mrq)3.8
Total Debt (mrq)58.12M
Total Debt/Equity (mrq)133.14
Current Ratio (mrq)5.96
Book Value Per Share (mrq)1.62

Cash Flow Statement

Operating Cash Flow (ttm)-93.11M
Levered Free Cash Flow (ttm)-56.16M